Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 1387 (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Haematological malignancies; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 31 Jan 2023 Status changed from recruiting to completed.
    • 12 Aug 2022 Planned End Date changed from 30 Jun 2021 to 30 Dec 2022.
    • 12 Aug 2022 Planned primary completion date changed from 31 Mar 2021 to 31 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top